Want to see AARD full AI Analyst Report?
AARD Stock Chart & Stats
$5.73
$0.37(5.85%)
At close: 4:00 PM EDT
$5.73
$0.37(5.85%)
Day’s Range― - ―
52-Week Range$3.35 - $17.23
Previous Close$6.69
Volume70.38K
Average Volume (3M)116.47K
Market Cap
$108.55M
Enterprise Value$52.64M
Total Cash (Recent Filing)$73.87M
Total Debt (Recent Filing)$677.00K
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Nov 12, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,884,846
10 Day Avg. Volume85,969
30 Day Avg. Volume116,472
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$5.25Price Target Upside-8.38% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-3.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageMinimal debt reduces solvency and refinancing pressure while preserving financial flexibility. Compared with the company’s equity base, the modest borrowing burden gives management more capacity to direct resources toward development and potentially absorb operating volatility.
Leadership ContinuityThe director elections reinforce continuity in governance during a critical development stage. Stable board leadership can support consistent strategic execution, preserve institutional knowledge, and reduce disruption as the company works toward advancing its biopharmaceutical programs.
Retention-oriented IncentivesRepricing certain options may improve employee retention and better align incentives with shareholder outcomes. Maintaining key personnel is strategically important for a small development-stage biotech whose progress depends heavily on specialized leadership and research expertise.
Bears Say
No Recorded RevenueThe absence of revenue means the business has not yet demonstrated commercial traction or an operating funding base. Until commercialization or partnering revenue arrives, continued development must be supported without recurring sales, leaving the company dependent on future financing or other capital sources.
Rapidly Widening LossesLosses are expanding materially rather than stabilizing, reflecting a rising cost base and heavier research and operating spending. Persistent deterioration increases the capital required to reach future milestones and leaves profitability highly dependent on successful development and eventual commercialization.
Heavy Ongoing Cash BurnDeeply negative operating and free cash flow indicate substantial ongoing funding needs for the current business scale. Continued cash consumption can erode the capital base over time and may require additional external funding, potentially limiting strategic flexibility as development spending continues.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.23 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $108.55M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 34 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.874 by $0.214.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Overvalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,884,846 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.874. Following the earnings report the stock price went down -8.623%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.25 (-8.38% Downside)
$5.25 (-8.38% Downside)
Blogger Sentiment
Neutral
AARD Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.50%
12-Months-Change
Fundamentals
Return on Equity
-71.54%
Trailing 12-Months
Asset Growth
-44.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$5.25
▼(-8.38% Downside)
Technical Analysis
Ownership Overview
14.60% Insiders
4.47% Mutual Funds
27.25% Other Institutional Investors
50.25% Public Companies and
Individual Investors